Phase II Trial of Zanubrutinib, Obinutuzumab, Bendamustine (ZGB) as First-Line Therapy for Chronic Lymphocytic Leukemia: A Single-Center Study
Clinical trial NCT07003464 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07003464
- Sponsor
- The First Hospital of Jilin University
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-15
- Primary completion
- 2027-06-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.